TABLE 3.
Inflammatory profile and anti‐oxidant status of individuals across FQS tertiles categories
| Tertiles of FQS | p | |||
|---|---|---|---|---|
| T1 (n = 55) | T2 (n = 57) | T3 (n = 59) | ||
| Inflammatory parameters | ||||
| WBC (109 cells/L) | 7.3 ± 2.4 | 7.1 ± 1.5 | 6.4 ± 1.4 | 0.026 a |
| Neutrophil (%) | 54.4 ± 11.8 | 53.3 ± 7.2 | 52.0 ± 10.3 | 0.51 |
| RDW (%) | 13.6 ± 1.5 | 13.1 ± 0.85 | 13.0 ± 0.81 | 0.040 a |
| MPV(fL) | 10.3 ± 1.0 | 10.3 ± 0.83 | 10.3 ± 0.93 | 0.98 |
| NLR | 1.8 ± 1.3 | 1.5 ± 0.56 | 1.2 ± 0.42 | 0.048 a |
| PLR | 8.5 ± 4.1 | 7.6 ± 2.4 | 6.6 ± 1.9 | 0.011 a , b |
| RPR | 0.05 ± 0.01 | 0.04 ± 0.01 | 0.05 ± 0.01 | 0.36 |
| hsCRP (mg/L) | 0.2 (0.01–0.37) | 0.4 (0.01–1.5) | 0.4 (0.1–1.0) | 0.051 |
| Anti‐oxidant status | ||||
| Urinary FRAP (μmol TAC/ mg Cr) | 6.0 ± 2.2 | 8.7 ± 7.6 | 11.1 ± 10.2 | 0.041 a , b |
| Urinary DPPH (mmol trolox equivalent/mg Cr) | 1.5 ± 0.71 | 2.3 ± 2.2 | 2.5 ± 1.5 | 0.032 a |
| Urinary MDA (μmol TBARs/mg Cr) | 0.87 ± 0.75 | 0.81 ± 0.79 | 0.83 ± 0.65 | 0.96 |
| Serum FRAP (μmol TAC/L) | 647 ± 82 | 671 ± 126 | 716 ± 144 | 0.030 a |
| Serum DPPH (mmol trolox equivalent/L) | 75.8 ± 59.1 | 94.3 ± 62.7 | 86.2 ± 54.4 | 0.38 |
| Serum MDA (μmol TBARs/L) | 0.57 ± 0.22 | 0.77 ± 0.57 | 0.70 ± 0.28 | 0.30 |
Note: Data presented as Mean ± SD or median (IQR). Significance of bold values were p < 0.05. Obtained from ANOVA test and post hoc Tukey.
Abbreviations: Cr, creatinine; DPPH, α, α‐diphenyl‐β‐picrylhydrazyl; FRAP, Ferric reducing/antioxidant power; hsCRP, high‐sensitivity C‐reactive protein; MDA, malondialdehyde; MPV, mean platelet volume; NLR, neutrophil: lymphocyte ratio; PLR, platelet: lymphocyte ratio; RDW, red blood cell distribution width; RPR, red blood cell distribution width: platelet ratio; WBC, White blood cell.
a
Significant between tertile 1 and 3.
b
Significant between tertile 2 and 3.